Literature DB >> 11601930

Venous limb gangrene during warfarin treatment of cancer-associated deep venous thrombosis.

T E Warkentin1.   

Abstract

BACKGROUND: The cause of cancer-associated venous limb gangrene is unknown but could paradoxically be due to warfarin.
OBJECTIVE: To determine the pathogenesis of venous gangrene in a patient with cancer.
DESIGN: Case report.
SETTING: University hospital in Ontario, Canada. PATIENT: 66-year-old woman with metastatic lung cancer and deep venous thrombosis. MEASUREMENTS: Levels of vitamin K-dependent factors, additional coagulation factors, and thrombin-antithrombin complexes (marker of thrombin generation).
RESULTS: During warfarin use, venous limb gangrene developed when the international normalized ratio (INR) reached 6.0 (therapeutic range, 2.0 to 3.0); at this time, the level of protein C (a vitamin K-dependent natural anticoagulant) was severely reduced, but thrombin-antithrombin complexes remained markedly elevated. The supratherapeutic INR was explained by the greatly reduced levels of factor VII, which correlated closely with protein C levels; therefore, the high INR was a surrogate marker for severely reduced protein C activity.
CONCLUSION: Warfarin may contribute to the pathogenesis of cancer-associated venous limb gangrene by leading to severe depletion of protein C while at the same time failing to reduce thrombin generation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11601930     DOI: 10.7326/0003-4819-135-8_part_1-200110160-00009

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  12 in total

Review 1.  Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  Walter Ageno; Alexander S Gallus; Ann Wittkowsky; Mark Crowther; Elaine M Hylek; Gualtiero Palareti
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

Review 2.  [Differential diagnosis and treatment of thrombocytopenia].

Authors:  V Kiefel; A Greinacher
Journal:  Internist (Berl)       Date:  2010-11       Impact factor: 0.743

Review 3.  Early recognition and treatment of pre-VITT syndrome after adenoviral vector-based SARS-CoV-2 vaccination may prevent from thrombotic complications: review of published cases and clinical pathway.

Authors:  Farid Salih; Siegfried Kohler; Linda Schönborn; Thomas Thiele; Andreas Greinacher; Matthias Endres
Journal:  Eur Heart J Open       Date:  2022-05-16

Review 4.  Low molecular weight heparin-induced skin necrosis-a systematic review.

Authors:  A E Handschin; O Trentz; H J Kock; G A Wanner
Journal:  Langenbecks Arch Surg       Date:  2004-11-27       Impact factor: 3.445

5.  Endogenous activated protein C limits cancer cell extravasation through sphingosine-1-phosphate receptor 1-mediated vascular endothelial barrier enhancement.

Authors:  Geerte L Van Sluis; Tatjana M H Niers; Charles T Esmon; Wikky Tigchelaar; Dick J Richel; Harry R Buller; Cornelis J F Van Noorden; C Arnold Spek
Journal:  Blood       Date:  2009-07-01       Impact factor: 22.113

6.  Warfarin-induced skin necrosis.

Authors:  Despoina D Kakagia; Nikolaos Papanas; Efthimios Karadimas; Alexandros Polychronidis
Journal:  Ann Dermatol       Date:  2014-02-17       Impact factor: 1.444

7.  Warfarin-induced Venous Limb Gangrene.

Authors:  Sarah Grim Hostetler; Jennifer Sopkovich; Steven Dean; Matthew Zirwas
Journal:  J Clin Aesthet Dermatol       Date:  2012-11

Review 8.  Heparin-Induced Thrombocytopenia: A Focus on Thrombosis.

Authors:  Gowthami M Arepally; Anand Padmanabhan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2020-12-03       Impact factor: 8.311

9.  Venous gangrene and cancer: a cool look at a burning issue.

Authors:  Khalid A Osman; Mohamed H Ahmed; Samir A Abdulla; Tim E Bucknall; Colin A Rogers
Journal:  Int Semin Surg Oncol       Date:  2007-03-27

Review 10.  Diagnosis and Treatment of Lower Extremity Deep Vein Thrombosis: Korean Practice Guidelines.

Authors:  Seung-Kee Min; Young Hwan Kim; Jin Hyun Joh; Jin Mo Kang; Ui Jun Park; Hyung-Kee Kim; Jeong-Hwan Chang; Sang Jun Park; Jang Yong Kim; Jae Ik Bae; Sun Young Choi; Chang Won Kim; Sung Il Park; Nam Yeol Yim; Yong Sun Jeon; Hyun-Ki Yoon; Ki Hyuk Park
Journal:  Vasc Specialist Int       Date:  2016-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.